Heartbeat becomes part of Saatchi & Saatchi Wellness

Share this article:
From left: Bill Drummy, Kathy Delaney and JD Cassidy
From left: Bill Drummy, Kathy Delaney and JD Cassidy

Publicis Groupe has announced that Heartbeat Ideas and Heartbeat West will join the network as a Saatchi & Saatchi health entity.

COO of the Publicis Groupe Jean-Yes Naouri stated in the release: “This is a reflection of our continued investment in digital and our faith in the power of health and wellbeing as an increase part of the world's conversation.”

The current New-York based Saatchi & Saatchi group—comprised of Saatchi & Saatchi Wellness and Saatchi & Saatchi Health Communications—will merge, and be known as Saatchi & Saatchi Wellness. Heartbeat and its sister agency will now operate under “Heartbeat Ideas, a member of Saatchi & Saatchi Wellness,” and “Heartbeat West, a member of Saatchi & Saatchi Wellness.”

Bill Drummy, Heartbeat Founder and CEO, commented in the release: “For fifteen years, we've been on a mission to bring a more effective, digitally forward approach to healthcare marketing. By becoming a member of the Publicis Groupe and Saatchi & Saatchi Wellness, we now have the opportunity to be a critical ingredient in an entirely new agency formulation for healthcare clients…”

Drummy remains at the helm at Heartbeat and joins a leadership team of Saatchi & Saatchi Wellness co-managing directors Kathy Delaney and JD Cassidy. Delaney will remain Global Creative Officer. The newly formed leadership team will report to Sam Welch, global group president of PHCG.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...